Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial
Nicola Dalbeth, Graeme Jones, Robert Terkeltaub, et al.
Arthritis & Rheumatology (2017) Vol. 69, Iss. 9, pp. 1903-1913
Open Access | Times Cited: 142

Showing 1-25 of 142 citing articles:

Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors
Mats Dehlin, L. Jacobsson, Edward Roddy
Nature Reviews Rheumatology (2020) Vol. 16, Iss. 7, pp. 380-390
Closed Access | Times Cited: 956
2020 American College of Rheumatology Guideline for the Management of Gout
John FitzGerald, Nicola Dalbeth, Ted R. Mikuls, et al.
Arthritis Care & Research (2020) Vol. 72, Iss. 6, pp. 744-760
Open Access | Times Cited: 654
2020 American College of Rheumatology Guideline for the Management of Gout
John FitzGerald, Nicola Dalbeth, Ted R. Mikuls, et al.
Arthritis & Rheumatology (2020) Vol. 72, Iss. 6, pp. 879-895
Open Access | Times Cited: 553
Gout
Nicola Dalbeth, Hyon K. Choi, Leo A. B. Joosten, et al.
Nature Reviews Disease Primers (2019) Vol. 5, Iss. 1
Closed Access | Times Cited: 480
Physiology of Hyperuricemia and Urate-Lowering Treatments
Caroline Benn, Vivek Dua, Rachel Gurrell, et al.
Frontiers in Medicine (2018) Vol. 5
Open Access | Times Cited: 273
U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia
William T. Crawley, Cyprien G. Jungels, Kurt R. Stenmark, et al.
Redox Biology (2022) Vol. 51, pp. 102271-102271
Open Access | Times Cited: 127
Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications
Sebastian E. Sattui, Angelo Gaffo
Therapeutic Advances in Musculoskeletal Disease (2016) Vol. 8, Iss. 4, pp. 145-159
Open Access | Times Cited: 125
Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study
Anne‐Kathrin Tausche, Rieke Alten, Nicola Dalbeth, et al.
Lara D. Veeken (2017) Vol. 56, Iss. 12, pp. 2170-2178
Open Access | Times Cited: 106
Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update
Arrigo F.G. Cicero, Federica Fogacci, Masanari Kuwabara, et al.
Medicina (2021) Vol. 57, Iss. 1, pp. 58-58
Open Access | Times Cited: 79
Pathophysiology of hyperuricemia and its clinical significance – a narrative review
Marta Skoczyńska, Małgorzata Chowaniec, Maciej Szymczak, et al.
Reumatologia/Rheumatology (2020) Vol. 58, Iss. 5, pp. 312-323
Open Access | Times Cited: 76
Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review
Robert Terkeltaub
Drugs (2023) Vol. 83, Iss. 16, pp. 1501-1521
Closed Access | Times Cited: 35
Gout therapeutics and drug delivery
Xiuju Peng, Xiaotong Li, Bing Xie, et al.
Journal of Controlled Release (2023) Vol. 362, pp. 728-754
Closed Access | Times Cited: 28
The substrate and inhibitor binding mechanism of polyspecific transporter OAT1 revealed by high-resolution cryo-EM
Tong‐Yi Dou, Tengfei Lian, Shi Shu, et al.
Nature Structural & Molecular Biology (2023) Vol. 30, Iss. 11, pp. 1794-1805
Open Access | Times Cited: 23
Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial
Austin G. Stack, Nalina Dronamraju, Joanna Parkinson, et al.
American Journal of Kidney Diseases (2020) Vol. 77, Iss. 4, pp. 481-489
Open Access | Times Cited: 57
Synthetic Approaches to the New Drugs Approved During 2020
Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 14, pp. 9607-9661
Closed Access | Times Cited: 29
Recent Progress and Future Perspectives on Anti-Hyperuricemic Agents
Zhiqiang Sun, Xuewen Zhang, Zean Zhao, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 22, pp. 19966-19987
Closed Access | Times Cited: 7
Potential Dangers of Serum Urate-Lowering Therapy
María Vanessa Pérez-Gómez, Lorenz-Alexander Bartsch, Esmeralda Castillo-Rodríguez, et al.
The American Journal of Medicine (2019) Vol. 132, Iss. 4, pp. 457-467
Closed Access | Times Cited: 51
Pegloticase treatment of chronic refractory gout: Update on efficacy and safety
Naomi Schlesinger, Peter E. Lipsky
Seminars in Arthritis and Rheumatism (2020) Vol. 50, Iss. 3, pp. S31-S38
Open Access | Times Cited: 42
Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials
Lisa K. Stamp, Christopher Frampton, Melanie Birger Morillon, et al.
The Lancet Rheumatology (2021) Vol. 4, Iss. 1, pp. e53-e60
Closed Access | Times Cited: 40
A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: Current therapeutic options and potential applications
Danni Song, Xu Zhao, Fuqi Wang, et al.
European Journal of Pharmacology (2021) Vol. 907, pp. 174291-174291
Closed Access | Times Cited: 37
2021 Asia‐Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout
Jose Paulo Lorenzo, Ma. Hanna Monica Z. Sollano, Evelyn O. Salido, et al.
International Journal of Rheumatic Diseases (2021) Vol. 25, Iss. 1, pp. 7-20
Closed Access | Times Cited: 33
Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout
Zihan Hou, Aijinxiu Ma, Jiale Mao, et al.
Expert Opinion on Drug Metabolism & Toxicology (2023) Vol. 19, Iss. 12, pp. 895-909
Closed Access | Times Cited: 16
Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis
Lisa K. Stamp, Melanie Birger Morillon, William J. Taylor, et al.
Seminars in Arthritis and Rheumatism (2018) Vol. 48, Iss. 2, pp. 293-301
Open Access | Times Cited: 40
Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials
David Fitzpatrick, Kent Roberson, Kiyoshi Niwa, et al.
Modern Rheumatology (2018) Vol. 29, Iss. 6, pp. 1042-1052
Open Access | Times Cited: 39
Systematic genetic analysis of early-onset gout: ABCG2 is the only associated locus
Faseeh Zaidi, Ravi Narang, Amanda Phipps‐Green, et al.
Lara D. Veeken (2019) Vol. 59, Iss. 9, pp. 2544-2549
Closed Access | Times Cited: 37
Page 1 - Next Page

Scroll to top